Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. (symbol: IPSC) is the issuer of record for a Form 4 filing submitted to the SEC. Truitt Joseph reported acquisition or exercise transactions in this Form 4 filing.
Century Therapeutics, Inc. (IPSC) reported that director Joseph Truitt received a grant of 148,000 stock options on September 9, 2026, each exercisable for one share of common stock at $2.03 per share and expiring on September 9, 2036. The options vest in equal monthly installments over 36 months, subject to his continued service to the company. Following this grant, he holds 148,000 options directly.
Century Therapeutics, Inc. (IPSC) filed an initial statement of beneficial ownership on Form 3 for Joseph Truitt, who is identified as a director of the company. The filing does not list any equity transactions, holdings, or derivative positions for Truitt and includes a remark referencing an Exhibit 24 Power of Attorney.
Century Therapeutics, Inc. (IPSC) reported that President and CEO Brent Pfeiffenberger had 463 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This tax-withholding disposition was priced at $2.11 per share, and he now directly holds 3,633,839 common shares. No Rule 10b5-1 trading plan is reported for this transaction.
Century Therapeutics, Inc. (IPSC) reported that Chief Technology and Manufacturing Officer Gregory Russotti sold 534 shares of common stock on September 8, 2026 at $2.05 per share. A footnote states these shares were sold automatically to cover tax withholding obligations related to vesting restricted stock units and not at his discretion.
After this transaction, Russotti held 511,785 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust. No Rule 10b5-1 trading plan is reported for these transactions.
Century Therapeutics, Inc. (IPSC) reported that Douglas Carr, its SVP Finance & Operations, had an automatic sale of 254 shares of common stock on September 8, 2026 at $2.05 per share. According to the footnote, the sale covered tax withholding obligations from vesting restricted stock units, was not discretionary, and left him holding 504,565 shares directly.
Century Therapeutics, Inc. (IPSC) expanded its Board of Directors from six to seven members and appointed Joseph Truitt as a Class I director effective September 9, 2026, with a term running to the 2028 annual stockholders’ meeting. Truitt will also serve on the Compensation Committee and has been deemed an independent director under Nasdaq rules.
For his board service, Truitt will receive an initial option to purchase 148,000 shares of common stock vesting in equal monthly installments over 36 months, plus an annual cash retainer of $40,000, under Century’s existing non‑employee director compensation program. Century highlighted continued progress of its pipeline, stating that CNTY‑813 remains on track for an IND submission in the fourth quarter of 2026 and that CNTY‑308 is anticipated to enter the clinic in 2026, both leveraging its Allo‑Evasion™ 5.0 platform.
Century Therapeutics, Inc. (IPSC) officer Gregory Russotti reported a proposed sale of 534 common shares, with an approximate sale date of September 8, 2026 and an aggregate market value of $1,094.43. The 534 shares were acquired through restricted stock vesting on September 4, 2026; the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. Russotti reported prior sales of 524 shares on June 8, 2026, for gross proceeds of $1,106.01, and 2,584 shares on June 12, 2026, for gross proceeds of $5,767.75.
Century Therapeutics, Inc. (IPSC) reported an insider tax-related share disposition by President and CEO Brent Pfeiffenberger. On 2026-08-14, 31,172 shares of common stock were withheld by the company at $1.92 per share to satisfy tax withholding obligations upon vesting of restricted stock units. After this withholding, Pfeiffenberger directly holds 3,634,302 shares of Century Therapeutics common stock.
Century Therapeutics, Inc. reported second quarter 2026 results and pipeline updates. The company is advancing CNTY-813, an iPSC-derived cell therapy for type 1 diabetes, having held a pre-IND meeting with the FDA that yielded alignment on its nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design. Phase 1 manufacturing has been established with consistent product quality, and an IND filing for CNTY-813 remains on track for the fourth quarter of 2026. CNTY-308 is planned to enter the clinic in 2026.
For the quarter ended June 30, 2026, Century reported no collaboration revenue, compared with $109.2 million in collaboration revenue in the first half of 2025. The company recorded a net loss of $34.6 million for the quarter and $56.2 million for the first half of 2026, versus net income of $44.0 million in the first half of 2025. Results include an $11.1 million loss on lease component termination. Research and development expenses declined to $19.6 million from $26.9 million in the prior-year quarter, and general and administrative expenses fell to $5.8 million from $7.8 million. As of June 30, 2026, cash and cash equivalents were $49.6 million, with short-term investments of $70.1 million and long-term investments of $77.5 million.
Century Therapeutics reported a larger net loss as collaboration revenue fell away but liquidity strengthened. For the quarter ended June 30, 2026, net loss was $34.6 million (six‑month loss $56.2 million) versus six‑month net income of $44.0 million a year earlier, when $109.2 million of Bristol‑Myers Squibb collaboration revenue was recognized.
Total assets were $287.0 million, including cash, cash equivalents and investments of $197.2 million. A January 2026 private placement raised about $126.4 million, increasing shares outstanding to 180.5 million. Management expects existing cash resources to fund operations into the first quarter of 2029.
Research and development and general and administrative expenses declined year over year, but results included an $11.1 million loss on a Philadelphia lease component termination. The company derecognized $3.8 million of contingent consideration after milestones expired and continues IND‑enabling work on lead programs CNTY‑813 and CNTY‑308.